Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
J Immunother Cancer
; 8(2)2020 07.
Article
in English
| MEDLINE | ID: covidwho-662488
ABSTRACT
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
Pneumonia, Viral
/
Coronavirus Infections
/
Antineoplastic Agents, Immunological
/
Neoplasms
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Year:
2020
Document Type:
Article
Affiliation country:
Jitc-2020-000952
Similar
MEDLINE
...
LILACS
LIS